<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498589</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2006-1</org_study_id>
    <nct_id>NCT00498589</nct_id>
  </id_info>
  <brief_title>Comparison of Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis</brief_title>
  <acronym>METEOR</acronym>
  <official_title>A Controlled, Randomized, Double-blind, Multicenter Study, Comparing Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  PHASE: II&#xD;
&#xD;
        -  TYPE OF STUDY : With direct benefit&#xD;
&#xD;
        -  DESCRIPTIVE: Multicenter, randomized, double-blind study&#xD;
&#xD;
        -  INCLUSION CRITERIA: Steroid-dependent ulcerative colitis&#xD;
&#xD;
        -  OBJECTIVES: To show superiority of methotrexate vs placebo in inducing steroid-free&#xD;
           remission in steroid-dependent ulcerative colitis&#xD;
&#xD;
        -  STUDY TREATMENTS: Methotrexate 1 intramuscular injection (25 mg) per week Placebo 1&#xD;
           intramuscular injection per week&#xD;
&#xD;
        -  NUMBERS OF PATIENTS: 55 patients in each group, i.e. a total of 110 patients&#xD;
&#xD;
        -  INCLUSION PERIOD: 24 months&#xD;
&#xD;
        -  STUDY DURATION: 36 months&#xD;
&#xD;
        -  EVALUATION CRITERIA: Remission without steroids, immunosuppressives and without&#xD;
           colectomy at 16 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative colitis (UC) is a chronic inflammatory bowel disease that slightly reduces life&#xD;
      expectancy, strongly reduces its quality and can lead to serious complications such as acute&#xD;
      colitis, dysplasia and colon cancer. About 40'000 patients are affected in France Among them,&#xD;
      15% suffer from a chronic active form that often leads to an extended steroid therapy, and&#xD;
      its known side effects. Azathioprine has already proven its efficacy in this indication but&#xD;
      brings a lasting remission without steroid in only 41% of the patients (1-4). What are the&#xD;
      medications available for the patients who failed in maintaining a remission with&#xD;
      azathioprine ? Cyclosporin is designed for severe or steroid-resistant forms. (5). The&#xD;
      results of two recent studies have showed that infliximab is more efficacious than placebo in&#xD;
      active UC (6, 7). Infliximab is expensive, its efficacy in steroid-dependent UC has not been&#xD;
      specifically tested yet, and its tolerance on the long term remains uncertain. Methotrexate&#xD;
      proved its efficacy in Crohn's disease with an intramuscular dose of 25mg/week (8). In UC a&#xD;
      controlled trial has been negative with an oral dose of 12.5mg/week (9). Another study&#xD;
      compared mercaptopurine, methotrexate (15mg/week) and 5-aminosalicylate in 72&#xD;
      steroid-dependent patients with CD or UC (10). The remission rates obtained were 58% after 30&#xD;
      weeks with methotrexate (not significantly different from 5-ASA) and 14% after 106 weeks (not&#xD;
      significantly different from 5-ASA). Few data are available on the efficacy of methotrexate&#xD;
      in UC, at a dose which is active in Crohn's disease (25mg intramuscular/week). Several&#xD;
      uncontrolled series have been published, including 91 patients whose remission failed under&#xD;
      azathioprine.&#xD;
&#xD;
      Methotrexate is cheap and its patent has fallen in the public domain. Only institutional&#xD;
      research will be able to finance a study in this new indication.&#xD;
&#xD;
      This is a prospective, controlled, randomized, double-blind study of methotrexate with an&#xD;
      intramuscular dose of 25mg/week vs placebo in patients with steroid-dependent UC.&#xD;
&#xD;
      This multicenter study will take place under the aegis of the Therapeutic Study Group for&#xD;
      Inflammatory Digestive Diseases (G.E.T.A.I.D.) and with the help of the gastroenterologists&#xD;
      network of the CIC. The issue of this study is important. If the hypothesis is borne out, a&#xD;
      cheap, efficacious medication will be available for chronic active UC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission without steroids, immunosuppressives and without colectomy</measure>
    <time_frame>week 16</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 IM or SC of placebo per week during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>25 mg per week IM or SC during 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one intramuscular injection per week</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  UC diagnosed according to the Lennard-Jones criteria (Appendix 1) with endoscopic&#xD;
             colorectal lesions, whatever their extension may be&#xD;
&#xD;
          -  A Mayo Disease Activity Index £ 4, with no item &gt;1 for the clinical part of the score&#xD;
             and from 0 to 2 for the endoscopic part at the time of inclusion&#xD;
&#xD;
          -  Steroid-dependence defined by at least 1 unsuccessful attempt to stop systemic steroid&#xD;
             therapy during the last 12 weeks. Steroid therapy might have been completely stopped&#xD;
             if it has been restarted within the last 30 days&#xD;
&#xD;
          -  To be receiving a treatment of prednisone at a dose between 10 and 40mg, stable for at&#xD;
             least 2 weeks at the time of inclusion&#xD;
&#xD;
          -  Under an adequate contraception for male or female subjects of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication to a colectomy.&#xD;
&#xD;
          -  Alcoholism (more than 21 glasses per week for male subjects and 14 glasses per week&#xD;
             for female subjects). 1 glass corresponds to 3 cl of strong alcohol, 10 cl glass of&#xD;
             wine or a half pint of beer.&#xD;
&#xD;
          -  Pregnant or breast-feeding female subjects.&#xD;
&#xD;
          -  No efficacious contraception.&#xD;
&#xD;
          -  NSAIDS or cotrimoxazole intake upon inclusion, or probenecid intake within 1 month&#xD;
             prior to inclusion.&#xD;
&#xD;
          -  Anti-TNFa treatment within 2 months prior to inclusion.&#xD;
&#xD;
          -  Azathioprine, mercaptopurine, cyclosporin or thalidomide within 1 month prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Modification of mesalazine or olsalazine dosage within 1 month prior to inclusion.&#xD;
&#xD;
          -  Chronic (broncho) pneumopathy.&#xD;
&#xD;
          -  Renal failure (creatinaemia &gt; upper limit of normal laboratory values limit).&#xD;
&#xD;
          -  Liver disease apart from primary sclerosing cholangitis.&#xD;
&#xD;
          -  Unexplained rise higher than twice the normal level for transaminases, alkaline&#xD;
             phosphatases and/or bilirubin.&#xD;
&#xD;
          -  Folate level &lt; normal level.&#xD;
&#xD;
          -  Past history of malignant condition (including leukaemia, lymphoma and myelodysplasia)&#xD;
             except for baso-cellular cutaneous cancers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Carbonnel</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB - Cliniques Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand - Hôpital Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hôpital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut L'Eveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne - Hôpital NOrd</name>
      <address>
        <city>Saint Priest</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel aviv</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano , Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Besancon</investigator_affiliation>
    <investigator_full_name>Franck Carbonnel</investigator_full_name>
    <investigator_title>PU-PH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

